Nektar Therapeutics (NKTR) Non-Current Deffered Revenue (2010 - 2020)

Nektar Therapeutics' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $2.5 million for Q4 2020.

• In Q4 2020, Non-Current Deffered Revenue fell 3.52% year-over-year to $2.5 million; the TTM figure through Dec 2020 stood at $2.5 million (down 3.52% YoY), while the FY2020 annual figure was $2.5 million, down 3.52% from the prior year.
• Non-Current Deffered Revenue for Q4 2020 stood at $2.5 million, down from $2.5 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $60.1 million in Q2 2016, with the low at $2.5 million in Q4 2020.
• The 5-year median for Non-Current Deffered Revenue is $12.1 million (2018), against an average of $24.5 million.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue retreated 1.51% in 2017, then plunged 79.71% in 2018.
• Nektar Therapeutics' Non-Current Deffered Revenue stood at $51.9 million in 2016, then plunged by 63.34% to $19.0 million in 2017, then slumped by 43.52% to $10.7 million in 2018, then tumbled by 76.23% to $2.6 million in 2019, then declined by 3.52% to $2.5 million in 2020.
• Business Quant data shows NKTR's Non-Current Deffered Revenue at $2.5 million in Q4 2020, $2.5 million in Q3 2020, and $2.5 million in Q2 2020.